Clinical Outcomes From Venetoclax Based Therapy in Patients With Relapsed/Refractory B-Cell Lymphomas

Hematological Oncology - United Kingdom
doi 10.1002/hon.221_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Cd19-Directed Car T Cell Therapy (Ctl019) for Relapsed/Refractory Diffuse Large B-Cell and Follicular Lymphomas: Four Year Outcomes

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Venetoclax Synergizes With Radiotherapy for Treatment of B-Cell Lymphomas

Cancer Research
Cancer ResearchOncology
2017English

Relapsed/Refractory ETP-all Successfully Treated With Novel Combination Therapy Venetoclax With Nelarabine Prior to Allogeneic Stem Cell Transplant

Pathology
Forensic MedicinePathology
2020English

Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Case Series of Nivolumab Treatment in Patients With Relapsed/Refractory Hiv-Related Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Gemcitabine Plus Liposomal Doxorubicin for Relapsed Refractory T-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Phase I Clinical Study of Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2017English

Outcomes in First Relapsed-Refractory Younger Patients With Mantle Cell Lymphoma: Results From the Mantle-First Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy